Leukopheresis will be performed using the pheresis machines at the Fred Hutchinson Cancer 
Research Center. 
3. Skin biopsy: The skin biopsy will be taken from your skin overlying the posterior pelvic bone 
or from your forearm. The skin is thoroughly cleansed, injected with local anesthetic, and 
the biopsy obtained using a 3 millimeter skin punch biopsy instrument. 
The procedures described above are all standard medical procedures. 
RISKS AND DISCOMFORT 
There is discomfort at the sites of skin biopsy and also from the insertion of the needle for blood drawing or 
leukopheresis. A bruise or hematoma (swelling) at the site of the needle puncture may develop. There is a 
slight risk of developing a local infection at the skin biopsy site, and there will be a small scar. 
ALTERNATIVES 
Should you or the respective transplant recipient choose not to participate in this study, the recipient will be 
eligible for a study designed to determine if bone marrow transplantation with the antiviral azidothymidine 
can be given safely and assist in the prevention of recurrent HIV infection. If the patient chooses to 
participate in this study, they would not be eligible to receive adoptive immunotherapy. 
BENEFITS 
Participation in this study will permit the evaluation of a new therapy to prevent the spread of HIV infection 
following bone marrow transplantation. The goal of this study is to evaluate the safety of reconstituting HIV- 
specific immunity in transplant patients early after transplant in the hopes of preventing recurrent HIV 
infection in the newly donated bone marrow. 
OTHER INFORMATION 
Your decision to participate in this study is voluntary, and you may withdraw at any time, for any reason, 
without notice and without prejudice. It is understood that all medical expenses related to or arising from 
these procedures will be paid by you and/or your insurance company. There will be no cost to you or the 
marrow recipient for the skin biopsy, blood draw and the culture of HIV-specific T lymphocytes. 
In order to evaluate the results of this study, your medical records will need to be available to other 
physicians or researchers associated with this project. The Food and Drug Administration and the National 
Cancer Institute will also have access to this information. All precautions to maintain confidentiality of 
medical records will be taken. Your personal identity will not be revealed in any publication or results. 
Study records will be maintained indefinitely for the purpose of analysis and follow-up. 
If you have questions about your rights as a research participant, please contact Karen Hansen in the 
Institutional Review Office of the Fred Hutchinson Cancer Research Center at 206-667-4867. 
Investigator’s Statement 
I have provided an explanation of the above research program. The subject was given an opportunity to 
discuss the procedures, including possible alternatives, and to ask any additional questions. A signed copy of 
this consent form has been given to the subject. 
Recombinant DNA Research, Volume 15 
[645] 
